ENTPD1 and rheumatoid arthritis: It has been suggested that targeted delivery of methotrexate (MTX) to the immunosuppressive NTPDase1/CD39+- and NT5E/CD73+-high macrophages might give better results in treating RA than the administration of MTX as such (Ohradanova-Repic et al., 2018).